Wellington Management Group LLP Has $74.58 Million Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK)

Wellington Management Group LLP raised its stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) by 763.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 1,725,622 shares of the company's stock after purchasing an additional 1,525,845 shares during the quarter. Wellington Management Group LLP owned 1.82% of Scholar Rock worth $74,581,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Global Retirement Partners LLC increased its holdings in shares of Scholar Rock by 584.7% during the 4th quarter. Global Retirement Partners LLC now owns 897 shares of the company's stock worth $39,000 after purchasing an additional 766 shares during the period. Nisa Investment Advisors LLC increased its stake in Scholar Rock by 1,321.8% in the fourth quarter. Nisa Investment Advisors LLC now owns 1,109 shares of the company's stock valued at $48,000 after acquiring an additional 1,031 shares during the period. GF Fund Management CO. LTD. bought a new stake in Scholar Rock in the fourth quarter valued at about $85,000. Amalgamated Bank increased its stake in Scholar Rock by 30.6% in the fourth quarter. Amalgamated Bank now owns 2,643 shares of the company's stock valued at $114,000 after acquiring an additional 620 shares during the period. Finally, KBC Group NV bought a new stake in Scholar Rock in the fourth quarter valued at about $131,000. Institutional investors own 91.08% of the company's stock.

Scholar Rock Price Performance

Shares of SRRK stock traded down $0.71 during trading hours on Friday, reaching $29.13. 1,368,000 shares of the company were exchanged, compared to its average volume of 1,270,418. Scholar Rock Holding Co. has a fifty-two week low of $6.76 and a fifty-two week high of $46.98. The stock's fifty day moving average is $30.38 and its two-hundred day moving average is $35.98. The company has a market cap of $2.77 billion, a price-to-earnings ratio of -12.40 and a beta of 0.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.88 and a quick ratio of 3.88.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last announced its earnings results on Wednesday, May 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.63) by ($0.04). During the same period in the prior year, the business posted ($0.59) EPS. Sell-side analysts forecast that Scholar Rock Holding Co. will post -2.42 earnings per share for the current fiscal year.

Insider Transactions at Scholar Rock

In other Scholar Rock news, insider Tracey Sacco sold 6,500 shares of the company's stock in a transaction that occurred on Monday, March 24th. The shares were sold at an average price of $33.08, for a total value of $215,020.00. Following the completion of the sale, the insider now owns 71,750 shares of the company's stock, valued at approximately $2,373,490. This represents a 8.31% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Kristina Burow sold 5,400 shares of the company's stock in a transaction that occurred on Thursday, May 29th. The shares were sold at an average price of $29.72, for a total transaction of $160,488.00. Following the completion of the sale, the director now directly owns 21,071 shares of the company's stock, valued at $626,230.12. The trade was a 20.40% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 181,798 shares of company stock worth $6,284,738. Corporate insiders own 13.30% of the company's stock.

Analysts Set New Price Targets

Separately, Wedbush reissued an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a research note on Wednesday, May 14th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, Scholar Rock has a consensus rating of "Buy" and a consensus price target of $42.67.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.